Functionalized Nanomaterials for Cancer Research

Applications in Treatments, Tools and Devices

1st Edition - March 21, 2024
Imprint: Academic Press
Editors: Hamed Barabadi, Ebrahim Mostafavi, Chaudhery Mustansar Hussain
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 5 1 8 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 5 5 1 9 - 2

Functionalized Nanomaterials for Cancer Research: Applications in Treatments, Tools and Devices presents an in-depth and step-by-step description of knowledge on functiona… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Functionalized Nanomaterials for Cancer Research: Applications in Treatments, Tools and Devices presents an in-depth and step-by-step description of knowledge on functionalized nanomaterials for cancer research, including treatment and future developments as well as their impact on patients’ overall outcomes. The book discusses functionalized nanoplatforms for cancer detection and imaging, interactions between nanomaterials and cancer cells, and drug resistant malignancies. The book's chapters are organized in a manner that can be readily adopted as sources for new and further studies by highlighting the main in vitro and in vivo nano-therapeutic achievements on cancer. Additionally, current trends on functionalized nanomaterials for cancer research and commercial scale opportunities are discussed. This is a valuable resource for researchers, oncologists, students, and members of the biomedical and medical fields who want to learn more about the potential of nanotechnology in cancer research and treatment.

Cover image
Title page
Table of Contents
Copyright
List of contributors
Part I: Introduction: Functionalized nanomaterials for cancer therapy research and new perspectives
Chapter 1. Cancer theranostics: recent global advances
Abstract
1.1 An introduction to cancer
1.2 An overview of theranostics
1.3 FDA-approved theranostic agents
1.4 Toxicity assessment of theranostics
1.5 Challenges
Acknowledgment
References
Chapter 2. Cancer nanotechnology: a new approach to upgrade cancer diagnosis and therapy
Abstract
2.1 Introduction
2.2 Nanotechnologies in cancer diagnosis
2.3 Nanotechnologies and cancer therapy
2.4 Cancer theragnostic
2.5 Nanotechnology clinical trials for cancer treatment
2.6 Challenges and future remarks
2.7 Conclusion
Acknowledgment
Conflict of interest
References
Chapter 3. Functionalized nanobiomaterials for cancer-targeted therapy: an overview
Abstract
3.1 Introduction
3.2 Classification
3.3 Nanobiomaterials’ generations
3.4 Nanobiomaterials characteristics need to be considered in therapeutic applications
3.5 Therapeutic applications of nanobiomaterials
3.6 Functionalized nanobiomaterials used in cancer therapy
3.7 Challenges to overcome for clinical translation
3.8 Concluding remarks
Acknowledgement
References
Part II: Functionalized nanomaterials for cancer therapy research: synthesis, manufacturing, and functionalization
Chapter 4. Recent innovations of nanomaterials in manufacturing processes
Abstract
4.1 The importance of nanotechnology
4.2 Nanotechnology in the pharmaceutical industry
4.3 Batch versus continuous manufacturing processes
4.4 Continuous manufacturing methodologies
4.5 Drug formulation using nanomaterials
4.6 Additive manufacturing in pharmaceuticals
4.7 Electrohydrodynamic atomization
4.8 Process analytical technology (PAT)
4.9 Conclusion
References
Chapter 5. Novel surface functionalization techniques for designing smart nanomaterials for cancer treatment
Abstract
5.1 Introduction
5.2 Surface functionalization of the nanomaterials
5.3 Nanomaterial fabrication/functionalization technique
5.4 Surface functionalization techniques
5.5 Surface functionalized smart nanoparticle techniques for cancer treatment
5.6 Conclusions
References
Part III: Functionalized nanomaterials for cancer research: applications
Chapter 6. Hybrid multifunctional nanomaterials for cancer diagnostics and therapeutics
Abstract
6.1 Introduction
6.2 Classification of hybrid nanomaterials
6.3 Synthesis of hybrid multifunctional nanomaterials
6.4 Hybrid nanomaterials in codelivery of combination treatments
6.5 Hybrid nanomaterial-based cancer imaging
6.6 Hybrid nanomaterials in photodynamic therapy and photodynamic diagnosis
6.7 Immune system stimulation by a multifunctional biomimetic platform
6.8 Hybrid multifunctional nanomaterials in cancer precision medicine
6.9 Conclusion and future perspectives
References
Chapter 7. Functionalized lipoplexes and polyplexes for cancer therapy
Abstract
7.1 Introduction
7.2 Choosing vector for gene therapy
7.3 Lipoplexes
7.4 Polyplexes
7.5 Lectin functionalized nanocarriers for gene delivery
7.6 Nanovectors for systemic siRNA transport
7.7 Future prospects and conclusion
References
Chapter 8. Functionalized exosomes for cancer therapy
Abstract
8.1 Introduction
8.2 Synthesis of functionalized exosome
8.3 Effect of functionalized exosome on immune cells
8.4 Targeting cellular signaling through functionalized exosome
8.5 Exosome as prognostic marker
8.6 Exosomal proteins as potential biomarkers for cancers
8.7 Challenges
8.8 Conclusion
References
Chapter 9. Functionalized Archaeosomes for Cancer Therapy
Abstract
9.1 Introduction
9.2 Nanoliposomes
9.3 Different types of liposomes, preparation methods, and their new generations
9.4 Application of liposomes
9.5 Structural properties and biosynthesis of archaeal lipids
9.6 Archaeal lipids: unusual physical properties and biomedical applications
9.7 Archaeosomes for targeted drug delivery: An insight
9.8 Surface modification of liposomes for targeted drug delivery
9.9 Functionalized archaeosomes as biological nanocarriers for anti-cancer agents
9.10 Challenges and limitations of archaeosomes for cancer therapy
9.11 Future perspective
References
Chapter 10. Functionalized bilosomes for cancer therapy
Abstract
10.1 Introduction
10.2 Photochemical nanosystems for cancer therapy
10.3 Properties of the bilosomes
10.4 Studies on the use of bilosomes as nanocarriers
10.5 Studies on the use of bilosomes in cancer therapy applications
10.6 Future perspectives and concluding remarks
10.7 Conclusion
References
Chapter 11. Functionalized bioengineered metal-based nanomaterials for cancer therapy
Abstract
11.1 Cancer: a global threat
11.2 Current cancer therapeutics: challenges and limitations
11.3 Nanotechnology: an overview
11.4 Unique properties of nanomaterials
11.5 Metal-based nanomaterials: properties and biomedical applications
11.6 Bioengineering of metal-based nanoparticles: an insight
11.7 Anticancer properties of bioengineered metal-based nanoparticles
11.8 Conclusions and future outlook
References
Chapter 12. Functionalized peptide and protein-based nanomaterials for cancer therapy
Abstract
12.1 Introduction
12.2 Types of protein and peptide nanocarriers
12.3 Synthesis strategies of peptide and protein-based nanocarriers
12.4 Functionalized nanoparticles
12.5 Applications of protein/peptide nanoparticles as delivery systems in cancer therapy
12.6 Outlooks
References
Chapter 13. Functionalized nanobody-based delivery systems for cancer diagnosis and therapeutic applications
Abstract
13.1 Introduction
13.2 Physical and biochemical characteristics of nanobody
13.3 Nanobody and cancer therapeutic strategies
13.4 Nanobody conjugates in cancer diagnosis
13.5 Nanobody and cancer therapy
13.6 Conclusion and future perspectives
References
Chapter 14. Functionalized phytosomes for cancer therapy
Abstract
14.1 Introduction
14.2 Phytosomes as drug delivery systems
14.3 Preparation of phytosome-based delivery systems
14.4 Targeted drug delivery of phytosomes
14.5 Effects of phytosomes on pharmacokinetic features
14.6 Application of phytosomes in cancer therapy
14.7 Conclusion
References
Chapter 15. Functionalized porphysomes and porphyrin-based nanomaterials for cancer therapy
Abstract
15.1 Introduction
15.2 Cancer theranostics using porphyrin-based nanomaterials
15.3 Different porphyrin-based nanoparticles cancer theranostic
15.4 Conclusion and future directions
Acknowledgment
References
Chapter 16. Functionalized liposomes and niosomes for cancer therapy
Abstract
16.1 Structure and properties of liposomes and niosomes
16.2 Preparation methods
16.3 Surface functionalized liposome/niosome
16.4 Targeting cancer cells with different surface functionalization
16.5 Smart responsive liposomes/niosomes and cancer therapy
16.6 Conclusion
References
Chapter 17. Functionalized dendrimers for cancer therapy
Abstract
17.1 Introduction
17.2 Dendrimers and their advantages and disadvantages
17.3 Brief history of dendrimers production
17.4 Dendrimers in drug delivery systems
17.5 Functionalized dendrimers
17.6 In vitro and in vivo studies
17.7 Preclinical and clinical trials
17.8 Prospects for the use of functionalized dendrimers in diseases, including cancer
17.9 Current status and prediction
17.10 Conclusion and future perspectives
References
Chapter 18. Functionalized polymersomes for cancer therapy
Abstract
18.1 Introduction
18.2 Design and preparation of polymersomes
18.3 Drug encapsulation in polymersomes
18.4 Mechanisms of drug release from polymersomes
18.5 Polymersomes in various cancer therapy
18.6 Theranostic application of polymersomes in cancer
18.7 Conclusion and future perspectives
References
Chapter 19. Functionalized quantum dot–based nanomaterials for cancer therapy
Abstract
19.1 Introduction
19.2 Synthesis of functionalized quantum dots
19.3 General anticancer mechanism of functionalized quantum dots
19.4 Anticancer activity of functionalized carbon-based quantum dots
19.5 Anticancer activity of functionalized Cd-based quantum dots
19.6 Anticancer activity of functionalized Zn-based quantum dots
19.7 Theranostics applications of functionalized quantum dots
19.8 Biosafety of functionalized quantum dots
19.9 Conclusion
References
Chapter 20. Functionalized magnetic nanoparticles for cancer therapy
Abstract
20.1 Introduction
20.2 Magnetic nanoparticles, their advantages, and disadvantages
20.3 Types of magnetic nanoparticles
20.4 A brief history of magnetic nanoparticles production
20.5 Magnetic nanoparticles in drug delivery systems
20.6 Functionalized magnetic nanoparticles
20.7 Current status and prediction
20.8 Conclusion and future perspectives
References
Chapter 21. Functionalized carbon-based nanomaterials for cancer therapy
Abstract
Graphical abstract
21.1 Introduction
21.2 Why carbon nanomaterials are suitable for biomedical applications, especially for cancer therapy?
21.3 Functionalization of carbon-based nanomaterials for cancer therapy
21.4 Cancer therapy methods by carbon-based nanocarriers
21.5 Types of carbon-based nanomaterials used in cancer treatment
21.6 Conclusions and perspectives
References
Chapter 22. Functionalized nanofibers for cancer therapy
Abstract
22.1 Introduction
22.2 Encapsulated cargoes for cancer therapy
22.3 Different release profiles in nanofibers
22.4 Functionalization approaches
22.5 Novel forms of functionalized nanofibers
22.6 Conclusion
References
Chapter 23. Applications of liposomes for overcoming cancer drug resistance
Abstract
Abbreviations
23.1 Introduction
23.2 Codelivery systems
23.3 Actively targeted systems
23.4 Trigger-responsive systems
23.5 Combinational and miscellaneous strategies
23.6 Conclusion and future directions
References
Chapter 24. New generation of composite carbon quantum dots for imaging, diagnosing, and treatment of cancer
Abstract
24.1 Introduction
24.2 New generation of composite carbon quantum dots
24.3 Nano and subnanoparticles for the cancer treatment
24.4 Problems and hurdles with quantum dots
24.5 Conclusion
References
Part IV: Functionalized nanomaterials: other aspects
Chapter 25. Functionalized nanomaterials: health and safety
Abstract
25.1 Introduction
25.2 Functionalized nanomaterials in vivo
25.3 Toxicity and safety concerns of functionalized nanomaterials
25.4 Developing sustainable nanomaterials for effective healthcare system
25.5 Conclusion and future perspective
References
Chapter 26. Commercial and regulatory challenges in cancer nanomedicine
Abstract
26.1 Introduction
26.2 Different aspects of cancer treatment and limitations of current methods
26.3 Rationale for the development of nanomedicines for cancer treatment: commercialization values
26.4 Nanomedicine global market and cancers currently diagnosed and treated using commercialized nanomedicines
26.5 Ecosystem of cancer nanomedicines and nanodiagnostics industry: the role of players and their share for existing challenges
26.6 The workflow from bench to bedside
26.7 Challenges in translation, commercialization, and regulations
26.8 Case studies
26.9 Future perspective
26.10 Conclusion
References
Chapter 27. Biocompatibility and toxicity challenges of nanomaterials
Abstract
Abbreviations
27.1 Introduction
27.2 What are biocompatibility and toxicity?
27.3 Types of nanomaterials for cancer therapy
27.4 Physicochemical parameters influencing biocompatibility and toxicity of nanomaterials
27.5 Cellular mechanisms of nanomaterial toxicity
27.6 Long-term risk assessment of nanomaterials
27.7 Conclusion and future perspective
Acknowledgements
References
Chapter 28. Functionalized nanomaterials and sustainable development
Abstract
28.1 Introduction
28.2 Green nanotechnology used to treat cancer
28.3 Nanomaterials’ functionalization
28.4 Methods for functionalizing nanoparticles
28.5 Green synthesis of modified nanomaterials
28.6 Design strategies and mechanisms of drug release
28.7 Approaches to functional nanomaterials in cancer therapy
28.8 Conclusion
Acknowledgements
References
Chapter 29. Cancer nanoimmunotherapy in the present scenario
Abstract
29.1 Introduction
29.2 Immune system (general aspects)
29.3 Immunotherapy
29.4 Nanomedicine
29.5 Nanoimmunotherapy
29.6 Clinical studies
29.7 Limitations
29.8 Perspectives
29.9 Conclusions
Acknowledgments
References
Chapter 30. Protein corona: challenges and opportunities for cancer therapy
Abstract
30.1 Introduction
30.2 Basis and theories of protein corona formation
30.3 Protein corona affects the therapeutic functions of nanoparticles
30.4 Several parameters are determinative in protein corona formation and its composition
30.5 Protein corona challenges the cancer nanomedicine performance
30.6 Protein corona affects the biosafety of nanoparticles
30.7 Protein corona: opportunities for cancer nanomedicine
30.8 Future perspective
30.9 Conclusion
References
Chapter 31. Nanomaterials affecting cellular metabolism: opportunities and challenges for cancer therapy
Abstract
31.1 Introduction
31.2 Metabolism of cancer cells in brief
31.3 Nanomaterials as metabolic stress and their effects on bioenergetics
31.4 Nanomaterials and upstream regulators of cellular metabolism
31.5 Effect of nanomaterials on lipid metabolism
31.6 Effect of nanomaterials on protein, peptide, and amino acid metabolism
31.7 Effect of nanomaterials on carbohydrate metabolism
31.8 Effect of nanomaterials on nucleic acid metabolism
31.9 Mechanisms and factors involved in nanomaterials’ effects on cellular metabolism: physiochemical properties of nanomaterials determine their effects on cellular metabolism
31.10 The effects of nanomaterials on cellular metabolism and treatment of cancer
31.11 Metabolomics as a tool to assess the effects of nanomaterials
31.12 Conclusion
References
Index

Hamed Barabadi

Dr. Hamed Barabadi (PharmD, PhD) works as an assistant professor in the Department of Pharmaceutical Biotechnology and associate dean of research affairs at the School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. He received a PhD degree from Shahid Beheshti University of Medical Sciences, Tehran, Iran, in 2019. He graduated as a Doctor of Pharmacy (PharmD) from Mazandaran University of Medical Sciences, Sari, Iran, in 2014. He owns to his credit a number of research papers, book chapters, and edited books with more than 3000 citations and Scopus H-index of 40. He has received many awards such as IET—Nanobiotechnology Premium Awards two times continuously in the years 2019 and 2020. Dr. Barabadi has been featured among the list of World’s Top 2% Scientists, according to a Stanford University study, 2020 and 2022. He is the guest editor/editor for various reputed indexed journals such as Current Nanomedicine, Nanoscience and Nanotechnology-Asia, Frontiers in Pharmacology, MDPI International Journal of Molecular Sciences, MDPI Molecules, and a few other prestigious journals. His research interests lie in the area of pharmaceutical nanobiotechnology, ranging from green synthesis, characterization, and optimization of nanobiomaterials to their pharmaceutical potential evaluations, such as anticancer, antimicrobial, and antioxidant. Moreover, he has collaborated actively with researchers in several other disciplines of pharmaceutical sciences, particularly the nanoformulation of drugs for drug delivery systems and nanomedicine.

Affiliations and expertise

Assistant Professor, Department of Pharmaceutical, Shahid Beheshti University, Iran

Ebrahim Mostafavi

Dr. Ebrahim Mostafavi has so far received training at Stanford University School of Medicine (PostDoc), Northeastern University (PhD), Harvard Medical School (Researcher), and University of Tehran (MSc and BSc). His research interests revolve around the engineering and development of (nano)biomaterials, nanocarriers, and 3D in vitro models (hydrogels, 3D bioprinted constructs, nanofibrous scaffolds, organoids, vascular grafts, and microfluidic systems) to create biologically complex systems for a range of applications such as cancer diagnostics and therapeutics, tissue engineering and regenerative medicine, biosensing, and infectious diseases. Dr. Mostafavi serves as an associate editor-in-chief of several prestigious and high-impact journals within Elsevier, Springer, Cell Press, Dove Medical Press, T&F, Frontiers, and so on He is also an editorial board member of more than 30 impactful and prestigious biomedical and materials science journals. His scholarly work comprises more than 200 publications with an H-index of 36 (i10-index of 105), including papers published in The Lancet family (i.e., Oncology, Infectious Diseases, Public Health, and Global Health) journals. So far, he has edited several books such as “Pharmaceutical Nanobiotechnology for Targeted Therapy” and “Emerging Nanomaterials and Nano-Based Drug Delivery Approaches to Combat Antimicrobial Resistance”. He has also contributed to leading more than 45 introductory book chapters in a very multidisciplinary field of bio/medical engineering, biotechnology, nanotechnology, materials science, and regenerative/ translational medicine.

Affiliations and expertise

Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA

Chaudhery Mustansar Hussain

Chaudhery Mustansar Hussain is an Adjunct Professor and Director of Laboratories in the Department of Chemistry & Environmental Sciences at the New Jersey Institute of Technology (NJIT), Newark, New Jersey, United States. His research is focused on the applications of nanotechnology and advanced materials, environmental management, analytical chemistry, and other industries. Dr. Hussain is the author of numerous papers in peer-reviewed journals as well as a prolific author and editor in his research areas. He has published with Elsevier, the American Chemical Society, the Royal Society of Chemistry, John Wiley & Sons, CRC Press, and Springer.

Affiliations and expertise

Adjunct Professor & Director of Laboratories, New Jersey Institute of Technology (NJIT), Newark, NJ, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Functionalized Nanomaterials for Cancer Research

Applications in Treatments, Tools and Devices

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Hamed Barabadi

Ebrahim Mostafavi

Chaudhery Mustansar Hussain

Related books